Identification of MUC1-C Dependence in Drug-Resistant Advanced Prostate Cancer Uncovers a Target for Antibody-Drug Conjugate Therapy

Researchers uncovered a common MUC1-C-dependent pathway in treatment-resistant castration resistant prostate cancer/neuroendocrine prostate cancer progression and identified MUC1-C as a target for their treatment with a M1C antibody-drug conjugate.